Antares Pharma Inc. ATRS was a big mover last session, as the company saw its shares rise more than 10% on the day. Shares moved up after the company along with Teva Pharmaceutical Industries Ltd announced the launch of the generic …
The company also gets F’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ONDK stock. Hi-Crush Partners LP. The company also gets F’s in sales growth, operating margin …
The stock is very attractive as an M&A target ... records are suggestive of continued progress in the clinic in the medium term. 16. Antares Pharma (ATRS) - The company possesses a strong pipeline of drug/device combination product …
and they also are very bullish on a mega-cap technology stock and a small-cap biotech. All are rated Buy at Jefferies. This small-cap biotech may prove to be a big-time winner for aggressive accounts. Antares Pharma Inc. (NASDAQ: ATRS) …
In after-hours, the stock was up 45.36% to $37.30 ... The FDA has declined to approve Antares Pharma Inc.'s (ATRS) Xyosted, a drug-device combination product, for the treatment of adult men with low testosterone associated with a …
A year ago, they were trading at $2.99. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ATRS at https://www.zacks.com/ap/ATRS
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly ... https://investorplace.com/2014/06/4-medical-devices-stocks-to-buy-now-wwin-atrs-nvcn/.